SHPH · Shuttle Pharmaceuticals Holdings, Inc. · Executive Compensation
$5.45
-0.10 (-1.80%)
At close · Oct 9
Return incl. dividend (before tax)
Going-concern doubt
— flagged Sep 24, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The successful completion of the acquisition or any other acquisition, or such financing, however, cannot be guaranteed. These conditions raise substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements contained in this report are issued.”View the 10-Q filed Sep 24, 2026
Market Cap
$26.44M
Shares
4.76M
Volume · Oct 9
29.46K
Avg daily vol (3M)
1.35M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Anatoly Dritschilo M.D | former CEO | $334,166 |
| Timothy J. Lorber | former CFO | $273,210 |
| Christopher Cooper | CEO | $193,549 |
| Peter Dritschilo | former President and former COO | $147,669 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Anatoly Dritschilo M.D | CEO\ | $274,000 |
| Michael Vander Hoek | VP, CFO\ \ | $269,848 |
| Peter Dritschilo | President and COO | $236,000 |
| Tyvin Rich | Chief Medical Officer | $218,000 |
| Timothy J. Lorber | CFO\ \ | $197,641 |
| Christopher Cooper | CEO | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Anatoly Dritschilo M.D | CEO\ | $399,175 |
| Tyvin Rich | Chief Medical Officer | $263,226 |
| Timothy J. Lorber | CFO\ \ | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Anatoly Dritschilo M.D | CEO | $268,921 |
| Peter Dritschilo | President and COO | $178,641 |
| Michael Vander Hoek | CFO, VP | $128,792 |
| Tyvin Rich | Chief Medical Officer | $96,077 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Anatoly Dritschilo M.D | CEO | $190,497 |
| Peter Dritschilo | President and COO | $109,867 |
| Michael Vander Hoek | CFO, VP | $64,338 |
| Tyvin Rich | Chief Medical Officer | $29,000 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Oleh Nabyt | independent director | Resigned | 2026-05-07 |
| Ryan Trasolini | Co-Chief Executive Officer | Appointed | 2026-05-07 |
| Sachin Pathigoda | director | Resigned | 2026-01-12 |
| Christopher Cooper | Chief Financial Officer (Principal Financial Officer) | Appointed | 2025-11-28 |
| Timothy Lorber | Chief Financial Officer | Resigned | 2025-11-28 |
| Angel Liriano | director | Appointed | 2025-09-18 |
| Sachin Pathigoda | director | Appointed | 2025-09-18 |
| Joseph Tung | director | Resigned | 2025-09-17 |
| Adam Chambers | director | Appointed | 2025-09-08 |
| Steven Richards | director | Resigned | 2025-09-05 |
| Peter Dritschilo | President, Chief Operating Officer and Secretary | Resigned | 2025-07-30 |
| Michael P. Vander Hoek | Vice President, Regulatory | Resigned | 2025-05-15 |
| Anatoly Dritschilo | director | Resigned | 2025-05-15 |
| Anatoly Dritschilo | Chief Scientific Offer | Resigned | 2025-05-15 |
| Anatoly Dritschilo | Chief Scientific Officer | Appointed | 2025-03-31 |
| Christopher Cooper | interim Chief Executive Officer | Appointed | 2025-03-31 |
| Christopher Cooper | interim co-Chief Executive Officer | Appointed | 2025-03-12 |
| Oleh Nabyt | director | Appointed | 2025-02-28 |
| Joseph Tung | director | Appointed | 2025-02-28 |
| George Scorsis | director | Appointed | 2025-02-28 |
| Chris Senanayake | director | Resigned | 2025-02-28 |
| Bette Jacobs | director | Resigned | 2025-02-28 |
| Milton Brown | director | Resigned | 2025-02-28 |
| Timothy Lorber | Chief Financial Officer | Appointed | 2024-06-18 |
| Timothy J. Lorber | part-time Chief Financial Officer | Appointed | 2024-06-18 |